Skip to main content
BioCentury, the Bernstein Report on BioBusiness
As published for the week of Monday, July 28, 2014


  • Cover Story: Strategy: Partnering Afrezza

    What challenges await potential partner for MannKind's Afrezza inhaled insulin

    By Stephen Hansen, Senior Writer

    Now that Afrezza has crossed the regulatory finish line, MannKind Corp.'s task is to find a partner willing to take on the large Phase IV safety trial that is required by FDA - and that may be necessary to support adoption by doctors and patients.

    After a five-year regulatory journey that included a complete response letter followed by two new Phase III trials, FDA approved Afrezza inhaled insulin on June 27 to improve glycemic control in Type I and II diabetics (see "Afrezza's Journey," page 6).

    Full Article

Money Raised in 2014

Last week, the biotech industry raised $452 million, bringing to $33.7 billion the total raised year-to-date. In 2013, a total of $37 billion was raised, including $14.4 billion in debt, $10 billion in follow-ons, $2.8 billion in PIPEs and other equity, $3.9 billion in IPOs, and $5.9 billion in venture capital. Totals include overallotments and warrants, and are rounded to the nearest millions.

Subscribe Now
Free Trial